Kronos Bio announced an update on its pipeline. After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia or AML , the Company has decided not to proceed to phase. The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner. Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase KAT domain of p300, a critical node of the IRF4 transcription regulatory network TRN. IRF4 is a key driver in multiple myeloma. KB-9558 is the second molecule to emerge from Kronos Bio’s proprietary product engine and is currently in IND-enabling studies, which are expected to be completed in the fourth quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRON:
- Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
- Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
- Kronos Bio reports Q3 EPS (54c), consensus (51c)
- Kronos Bio to reduce workforce by 19% in restructuring